Kadimastem, an Israeli biopharma venture, recently declared it was hoping to discuss with the U.S. Food and Drug Administration (FDA) its AstroRX cells experimental therapy, after demonstrating promising results with cohort AM of its Phase I/IIa clinical trials for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).
TrialSite News probes this news coming out of Israel via the Jerusalem Post. ALS is a deadly disease that afflicts about 450,000 worldwide according to the ALS Therapy Development Institute.
Known as Lou Gehrig’s disease the disease causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common.
What is Kadimastem’s AstroRX?
AstroRX is a stem cell therapy developed by Kadimastem. The U.S. FDA granted the experimental cell therapy orphan drug status for the treatment of ALS in November 2018.
Astrocytes are star-shaped cells of the central nervous system that play a key role in maintaining a healthy brain environment. It has been evidenced that malfunctioning astrocytes play a key role in ALS disease progression. One study,...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).